Johnson & Johnson said Monday that it plans to have enough doses of its vaccine for more than 20 million Americans by the end of March if its vaccine is authorized by the Food and Drug Administration.

The vaccine is being eagerly awaited as the next in line to join the COVID-19 vaccines already in use from Pfizer and Moderna. An FDA advisory committee is meeting Friday to consider the application, and emergency authorization could come soon after.

Join BJL on WhatsApp Status: Click here to Join BJL status for engagements, births, deals, levayos, events & more

Join BJL on WhatsApp Groups: Click here to Join an official BJL WhatsApp group for breaking news as it happens

The company for the first time on Monday gave some specificity regarding the number of doses it will have immediately available. The vaccine, unlike those from Pfizer and Moderna, requires only one dose, so 20 million doses would completely vaccinate 20 million people.

"Assuming necessary regulatory approvals relating to our manufacturing processes, our plan is to begin shipping immediately upon emergency use authorization, and deliver enough single-doses by the end of March to enable the vaccination of more than 20 million Americans," Richard Nettles, vice president of U.S. medical affairs for Janssen Pharmaceuticals, a part of Johnson & Johnson, said in prepared remarks for the House Energy and Commerce Committee. The remarks were posted online by the committee ahead of Tuesday's hearing with several vaccine manufacturers. Read more at The Hill